Neutropenia - Pipeline Review, H1 2017

Published: Apr, 2017 | Pages: 85 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neutropenia - Pipeline Review, H1 2017, provides an overview of the Neutropenia (Hematological Disorders) pipeline landscape.

Neutropenia is an abnormally low count of neutrophils, a type of white blood cell that helps fight off infections, particularly those caused by bacteria and fungi. Signs and symptoms include fevers, frequent infections, mouth ulcers, gum infections and dysuria.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neutropenia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Neutropenia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neutropenia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neutropenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 4, 2, 1, 4, 3, 1, 8 and 3 respectively.

Neutropenia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Neutropenia (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Neutropenia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Neutropenia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Neutropenia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Neutropenia (Hematological Disorders)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Neutropenia (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Neutropenia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Neutropenia - Overview
Neutropenia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Neutropenia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neutropenia - Companies Involved in Therapeutics Development
Adello Biologics LLC
Apotex Inc
Arven Ilac
BeyondSpring Pharmaceuticals Inc
Cellerant Therapeutics Inc
Cleveland BioLabs Inc
Coherus BioSciences Inc
Dr. Reddy's Laboratories Ltd
Eurofarma Laboratorios SA
Intas Pharmaceuticals Ltd
Ligand Pharmaceuticals Inc
Lupin Ltd
Mycenax Biotech Inc
Prolong Pharmaceuticals LLC
Richter Gedeon Nyrt
Sandoz International GmbH
USV Pvt Ltd
Neutropenia - Drug Profiles
ACN-8337 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARVMIC-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CBLB-612 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
filgrastim biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LG-7455 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim (recombinant) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
plinabulin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
romyelocel-L - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tamibarotene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neutropenia - Dormant Projects
Neutropenia - Product Development Milestones
Featured News & Press Releases
Apr 25, 2017: Coherus BioSciences Completes Patent Dance Exchange with Amgen for Neulasta Biosimilar
Apr 25, 2017: BeyondSpring Enrolls First US Patient in Phase 2/3 Clinical Trial of Plinabulin for Neutropenia Prevention
Mar 14, 2017: BeyondSpring Chief Medical Officer to Present Clinical Data for Lead Asset Plinabulin for Non-Small Cell Lung Cancer Treatment and Neutropenia Prevention at 2017 BIO Asia International Conference in Tokyo
Jan 27, 2017: Withdrawal of the marketing authorisation application for Zioxtenzo (pegfilgrastim)
Nov 01, 2016: Prolong Pharmaceuticals Presents Data on Toxicology, Pharmacokinetics and Pharmacodynamics of ANF-RHO
Sep 09, 2016: Apobiologix Announces Victory Over Amgen in Biosimilar (filgrastim) Patent Case
Sep 09, 2016: Apobiologix Announces Victory Over Amgen in Biosimilar (pegfilgrastim) Patent Case
Jul 11, 2016: Coherus Announces Positive Topline Results For CHS-1701 (Pegfilgrastim Biosimilar Candidate) Pharmacokinetic And Pharmacodynamic Biosimilarity Study
May 26, 2016: American Society of Clinical Oncology Selects BeyondSpring Abstract on Neutropenia Mitigation with Plinabulin Use for Publication
Mar 31, 2016: Launch of Key Biosimilar Medicine To Help Save Healthcare Budgets
Feb 11, 2016: Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim
Feb 01, 2016: Coherus Announces CHS-1701 (Neulasta Biosimilar) Met Both Primary Endpoints in Registration-Enabling Immunogenicity Study
Dec 21, 2015: Coherus BioSciences Signs Strategic Manufacturing Agreement With KBI Biopharma for Commercial Supply of CHS-1701
Dec 08, 2015: Coherus BioSciences Reports Update to CHS-1701 Program
Dec 07, 2015: Phase III Data Shows Sandoz' Proposed Biosimilar Pegfilgrastim has Similar Safety and Efficacy as the Reference Product
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Neutropenia, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Neutropenia - Pipeline by Adello Biologics LLC, H1 2017
Neutropenia - Pipeline by Apotex Inc, H1 2017
Neutropenia - Pipeline by Arven Ilac, H1 2017
Neutropenia - Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2017
Neutropenia - Pipeline by Cellerant Therapeutics Inc, H1 2017
Neutropenia - Pipeline by Cleveland BioLabs Inc, H1 2017
Neutropenia - Pipeline by Coherus BioSciences Inc, H1 2017
Neutropenia - Pipeline by Dr. Reddy's Laboratories Ltd, H1 2017
Neutropenia - Pipeline by Eurofarma Laboratorios SA, H1 2017
Neutropenia - Pipeline by Intas Pharmaceuticals Ltd, H1 2017
Neutropenia - Pipeline by Ligand Pharmaceuticals Inc, H1 2017
Neutropenia - Pipeline by Lupin Ltd, H1 2017
Neutropenia - Pipeline by Mycenax Biotech Inc, H1 2017
Neutropenia - Pipeline by Prolong Pharmaceuticals LLC, H1 2017
Neutropenia - Pipeline by Richter Gedeon Nyrt, H1 2017
Neutropenia - Pipeline by Sandoz International GmbH, H1 2017
Neutropenia - Pipeline by USV Pvt Ltd, H1 2017
Neutropenia - Dormant Projects, H1 2017
Neutropenia - Dormant Projects, H1 2017 (Contd..1), H1 2017